Prof. Dr Alexander Dityatev and his team won first place in the category ‘most innovative projects in basic research’ for their new approach to the treatment of dementia and psychological disorders. They have developed a therapeutic agent similar to the glycan PolySia that is produced naturally in the body and can inhibit neurodegenerative…
The cooperation agreement sets down the way in which research activities and grants are distributed, and how the partners deal with IP arising during the cooperation. On the basis of the agreement, the participating institutes, coordinated by the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC), have already commenced…
You will come away with exciting insights, practical tips and valuable contacts. Entrepreneurs, experienced managers, investors and experts gather in a uniquely informal atmosphere to compare notes on current trends and support start-ups. The programme includes keynote presentations, a panel discussion led by Prof. Horst Domdey and a pitch…
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The licence refers to an intellectual property portfolio owned by the MDC covering novel chimeric antigen receptor (CAR) constructs that specifically bind B-cell maturation…
The German Association for Certification has confirmed that Ascenion complies with the quality management system requirements of European norm DIN EN ISO 9001:2015. The certification covers Ascenion’s entire spectrum of services: evaluation and commercialization of life-science inventions, support of start-ups, and investment management. “This is…
Don’t miss your chance to secure a spot at next year’s BioVaria, 27 – 28 April 2020 in Munich! Application for European startups is now open until 14th February 2020. Selected teams and companies will benefit from the two-day Startup Pitch & Partner program designed to promote your business amongst leading European life-science investors and…
The NUVISAN group, an international service provider for clinical studies, contract development and manufacturing (CRO/CDMO) with headquarters in Neu-Ulm, has acquired the Munich company Inamed GmbH. Ascenion’s oldest portfolio company has thus found the ideal partner with which to continue its more than 20 year-old success story. The Inamed team,…
Ascenion’s portfolio company Photonion GmbH offers innovative mass spectrometry systems that allow a more detailed analysis of air pollutants, especially polycyclic aromatic hydrocarbons (PAHs). PAHs are considered particularly damaging to humans and the environment. The new measurement method is based on a proprietary ionisation and detection…
Learn about the milestones we reached together with our partners in 2018, the revenues we generated and interesting emerging trends. The key points at a glance:
3 further research institutes gained as long-term partners, making a total of 28 public research institutes in Europe supported by us 119 invention disclosures assessed for…
Should public research institutes and universities receive equity in start-ups founded to commercialize their intellectual property? And if so, how much? These questions are often hotly debated during the founding of start-ups, costing a huge amount of time, and often resulting in a lot of bad feeling. Together with a number of research…
Check out our new website design to help you find what you need:
Information about us and our services Technology offers from our partner institutes News from knowledge and technology transfer
We have optimized the structure, search and filtering options for you and have refreshed the layout. There is a lot to discover. For…
19 September 2019, Munich, Germany - Ascenion GmbH, technology transfer partner of the Helmholtz Centre for Infection Research (HZI), announces the take-over of its portfolio company WBC Drug Delivery Technologies (WBC) by Klaria Pharma Holding AB in an all-stock deal.
WBC was founded earlier this year to further advance a new drug delivery…
More than 1,300 delegates from 35+ countries, such as big pharma, emerging and small biotech, diagnostics companies, pre-seed, seed and Series-A investors, as well as professionals from tech transfer, academia and research institutions will come together in December for BioFIT, a partnering event in Europe for technology transfer,…
